Interview: Janssen Builds Japan Specialty Interests But Wants Ongoing Policy Debate
Janssen’s Japan country president says while the company is committed to pursuing innovation, from a policy angle it would like to see this adequately rewarded, given the broader societal benefits it can bring. Amid increasing competition from the rest of Asia, the executive says Japan also has the chance to take a global research leadership position through appropriate reforms.
You may also be interested in...
Asia Executives On The Move: Sanofi's Global R&D Head Moves To Innovent
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
Asia Executives On The Move: Senior Changes At Biogen, Amicus, PhRMA In Japan, Ascletis and Lupin
The coming of autumn ushers in a flurry of executive changes. Biogen has a new R&D head for Japan while Amicus Japan has a new president, and other executive changes take place at Ascletis, Lupin and industry trade groups PhRMA and IPA.
Japan R&D Industry Presents United Front On Policy Reforms
Following pricing reforms earlier this year that industry saw as generally unfavorable, major pharma associations in Japan present a united front in calling for a broad range of policy revisions to promote an ecosystem that better fosters and rewards innovation.